Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 east Monument street #333 Baltimore, MD 21287, USA.
Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 east Monument street #333 Baltimore, MD 21287, USA.
Endocrinol Metab Clin North Am. 2023 Jun;52(2):245-257. doi: 10.1016/j.ecl.2022.10.003. Epub 2022 Nov 16.
Growth hormone (GH) secretion declines with aging (somatopause). One of the most controversial issues in aging is GH treatment of older adults without evidence of pituitary pathology. Although some clinicians have proposed reversing the GH decline in the older population, most information comes from not placebo-controlled studies. Although most animal studies reported an association between decreased GH levels (or GH resistance) and increased lifespan, human models have shown contradictory reports on the consequences of GH deficiency (GHD) on longevity. Currently, GH treatment in adults is only indicated for individuals with childhood-onset GHD transitioning to adulthood or new-onset GHD due to hypothalamic or pituitary pathologic processes.
生长激素(GH)的分泌随着年龄的增长(somatopause)而下降。衰老研究中最具争议的问题之一是,没有垂体病理证据的老年人使用 GH 治疗。尽管一些临床医生提出了在老年人群中逆转 GH 下降的方案,但大多数信息来自非安慰剂对照的研究。尽管大多数动物研究报告了 GH 水平降低(或 GH 抵抗)与寿命延长之间的关联,但人体模型对 GH 缺乏(GHD)对长寿的影响的报告却相互矛盾。目前,GH 治疗仅适用于从儿童期开始出现 GHD 过渡到成年期的个体,或由于下丘脑或垂体病理过程而出现新发性 GHD 的个体。